[1] Nabhan M, Louka ML, Khairy E, et al.MicroRNA-181a and its target Smad 7 as potential biomarkers for tracking child acute lymphoblastic leukemia[J]. Gene, 2017, 628: 253-258. [2] Lee P, Bhansali R, Izraeli S, et al.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome[J]. Leukemia, 2016, 30(9): 1816-1823. [3] Gutierrez-Camino A, Garcia-Obregon S, Lopez-Lopez E, et al.miRNA deregulation in childhood acute lymphoblastic leukemia: a systematic review[J]. Epigenomics, 2020, 12(1): 69-80. [4] Wang J, Zhang KY, Liu SM, et al.Tumor-associated circulating microRNAs as biomarkers of cancer[J]. Molecules, 2014, 19(2): 1912-1938. [5] Du X, Zhang J, Wang J, et al.Role of miRNA in Lung Cancer-Potential Biomarkers and Therapies[J]. Curr Pharm Des, 2018, 23(39): 5997-6010. [6] Cutrona G, Matis S, Colombo M, et al.Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy[J]. Leukemia, 2017, 31(9): 1894-1904. [7] Shafik RE, Abd El Wahab N, Senoun SA, et al. Expression of Micro-RNA 128 and Let-7b in Pediatric Acute Lymphoblastic Leukemia Cases[J]. Asian Pac J Cancer Prev, 2018, 19(8): 2263-2267. [8] Zhang Y, Li H, Cao R, et al.Suppression of miR-708 inhibits the Wnt/beta-catenin signaling pathway by activating DKK3 in adult B-all[J]. Oncotarget, 2017, 8(38): 64114-64128. [9] Bhojwani D, Yang JJ, Pui CH.Biology of childhood acute lymphoblastic leukemia[J]. Pediatr Clin North Am, 2015, 62(1): 47-60. [10] Sun C, Chang L, Zhu X.Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse[J]. Oncotarget, 2017, 8(21): 35445-35459. [11] Pui CH, Mullighan CG, Evans WE, et al.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?[J]. Blood, 2012, 120(6): 1165-1174. [12] Kizilocak H, Okcu F.Late Effects of Therapy in Childhood Acute Lymphoblastic Leukemia Survivors[J]. Turk J Haematol, 2019, 36(1): 1-11. [13] Piatopoulou D, Avgeris M, Drakaki I, et al.Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia[J]. Ann Hematol, 2018, 97(7): 1169-1182. [14] Ghodousi ES, Rahgozar S.MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia[J]. J Cell Biochem, 2018, 119(7): 6024-6032. [15] Saini S, Majid S, Shahryari V, et al.miRNA-708 control of CD44(+) prostate cancer-initiating cells[J]. Cancer Res, 2012, 72(14): 3618-3630. [16] Yang H, Su H, Hu N, et al.Integrated analysis of genome-wide miRNAs and targeted gene expression in esophageal squamous cell carcinoma (ESCC) and relation to prognosis[J]. BMC Cancer, 2020, 20(1): 388. [17] Duyu M, Durmaz B, Gunduz C, et al.Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia[J]. Biomed Res Int, 2014, 2014: 967585. [18] Candia J, Cherukuri S, Guo Y, et al.Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach[J]. Converg Sci Phys Oncol, 2015, 1(2): 025002. [19] de Oliveira JC, Scrideli CA, Brassesco MS, et al. MiR-708-5p is differentially expressed in childhood acute lymphoblastic leukemia but not strongly associated to clinical features[J]. Pediatr Blood Cancer, 2015, 62(1): 177-178. |